Headquarters
111 AVENUE DE FRANCE, PARIS 13, ILE-DE-FRANCE 75013, FR
PARIS 13, ILE-DE-FRANCE, FR
ELIGO BIOSCIENCE
From the company
Eligo Bioscience is deploying in vivo gene editing technologies against microbiome targets to address diseases with high unmet needs. It has developed a first-in-class proprietary GEM (Gene Editing of the Microbiome) platform to edit the microbiome gene repertoire in vivo, and was founded by the inventors of CRISPR-based bacterial precision killing.
Products & services offered
Facilities
Send your requirements
Quantities, certifications, and timing.